Clin2
NCT05301881Possibly a fitRecruiting

Keep the same treatment after limited metastatic growth

Breast Cancer InvasiveMetastatic CancerOligoprogressive

Part of Cancer clinical trials.

This study tests whether continuing your current systemic (whole-body) therapy is safe and helpful when only 1–2 metastatic spots start growing. It also checks whether adding local treatment (such as radiation or ablation) to those spots can better control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
118 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have confirmed invasive breast cancer that has spread (metastatic).
  • Your cancer is growing in only 1–2 places (“oligoprogression”) and it’s limited to one organ, or a nearby primary/lymph-node area.
  • You have been on your current whole-body treatment for at least 6 months, with stable disease or partial/complete response for at least 6 months.
  • Scans show the limited growth within about 70 days before the local treatment, and you can have a follow-up FDG-PET-CT scan 5–7 weeks later.
  • The new growing spot(s) can be treated locally (surgery, radiation, or radiofrequency ablation) with the goal of destroying them.
  • You’re age 18 or older and can do usual activities (WHO performance status 0–1).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06103669Recruiting
Local treatment for limited cancer spread

This trial tests whether using local treatments (like targeted radiation or ablation) on a few new spots of cancer can help people whose cancer is otherwise stable on their current treatment. It enrolls people with various solid tumors, such as breast, gynecologic, head & neck, sarcoma, or other types.

Sacramento, California
NCT06103682Recruiting
Treating growing lung spots with local therapy

This trial tests if focusing treatment on a few new or growing lung tumors can help people with lung cancer who are already on systemic therapy. You may qualify if you have stable disease overall but a small number of new spots that can be safely treated with radiation or other local procedures.

Sacramento, California
NCT06101290Recruiting
Local therapy for progressing spots in genitourinary cancers

This trial explores whether treating only the new or growing spots of cancer (called oligoprogression) with local therapies like radiation or ablation can help you stay on your current systemic treatment longer. It is for people with prostate, bladder, or kidney cancer that has started to progress in a few places.

Sacramento, California
NCT06925984Recruiting
Targeted radiation for breast cancer that has spread and is growing a little

This trial tests whether giving focused, high-dose radiation to spots where the cancer is growing can help control the disease while you stay on your current hormone therapy and/or CDK4/6 inhibitor. It is for people with ER+/HER2- breast cancer that has spread to a few places and is slowly starting to progress.

Brussels
NCT07545486Not yet recruiting
Ablative Therapy for Cancer After Initial Treatment Response

This trial tests whether destroying remaining cancer spots with targeted ablation (surgery, radiation, or other local treatments) after your cancer has responded to initial chemotherapy or immunotherapy can help you live longer. You must have a few remaining tumors that can be treated locally.

Brussels
NCT06367972Recruiting· Phase 2/Phase 3
Extending systemic therapy with local treatment for limited cancer growth

This trial tests whether adding local treatments like radiation or surgery to standard therapy can help control cancer that has started to grow in just a few spots. It is for people with certain advanced cancers that have 1 to 5 growing lesions that can be treated locally.

Houston, Texas

Hear when a new Breast Cancer Invasive trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.